We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

161 hedge funds and large institutions have $586M invested in Allogene Therapeutics in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 54 increasing their positions, 46 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

393% more call options, than puts

Call options by funds: $1.28M | Put options by funds: $260K

47% more capital invested

Capital invested by funds: $398M → $586M (+$188M)

17% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 46

3.96% more ownership

Funds ownership: 73.64% → 77.6% (+4%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less funds holding

Funds holding: 170 → 161 (-9)

28% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 32

Holders
161
Holders Change
-9
Holders Change %
-5.29%
% of All Funds
2.32%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
23
Increased
54
Reduced
46
Closed
32
Calls
$1.28M
Puts
$260K
Net Calls
+$1.02M
Net Calls Change
+$1.38M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$28.2M
2
BC
Boxer Capital
California
+$16.1M
3
FLSM
Frazier Life Sciences Management
California
+$12M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$7.54M
5
VPC
Vestal Point Capital
New York
+$5.63M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$8.52M
2
JP Morgan Chase
JP Morgan Chase
New York
-$7.2M
3
Millennium Management
Millennium Management
New York
-$7.17M
4
Morgan Stanley
Morgan Stanley
New York
-$4.61M
5
Citadel Advisors
Citadel Advisors
Florida
-$3.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
OCA
26
Octagon Capital Advisors
New York
$3.22M +$3M +720,000 New
Citigroup
27
Citigroup
New York
$3.03M +$2.69M +643,905 +1,876%
SCM
28
Superstring Capital Management
New York
$2.33M +$1.25M +299,137 +135%
UBS Group
29
UBS Group
Switzerland
$2.32M +$1.41M +338,006 +187%
ZIM
30
Zacks Investment Management
Illinois
$2.06M +$281K +67,357 +17%
TD Asset Management
31
TD Asset Management
Ontario, Canada
$1.96M +$833K +199,600 +84%
CANY
32
Caxton Associates (New York)
New York
$1.93M -$1.43M -343,907 -44%
Cerity Partners
33
Cerity Partners
New York
$1.9M -$390K -93,412 -18%
CBA
34
Coastal Bridge Advisors
Connecticut
$1.82M – – –
Bank of America
35
Bank of America
North Carolina
$1.81M +$307K +73,494 +22%
Renaissance Technologies
36
Renaissance Technologies
New York
$1.77M -$258K -61,748 -13%
Mirae Asset Global Investments
37
Mirae Asset Global Investments
South Korea
$1.77M +$694K +166,433 +85%
N
38
Nuveen
North Carolina
$1.35M -$231K -55,303 -15%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$1.34M -$97.8K -23,428 -7%
SFI
40
Susquehanna Fundamental Investments
Pennsylvania
$1.28M +$1.2M +286,408 New
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.26M +$321K +76,916 +37%
Mitsubishi UFJ Asset Management
42
Mitsubishi UFJ Asset Management
Japan
$972K -$15K -3,599 -2%
Swiss National Bank
43
Swiss National Bank
Switzerland
$960K – – –
Millennium Management
44
Millennium Management
New York
$901K -$7.17M -1,717,544 -90%
Prudential Financial
45
Prudential Financial
New Jersey
$887K -$753K -180,428 -48%
D.E. Shaw & Co
46
D.E. Shaw & Co
New York
$875K +$501K +120,138 +159%
Ameriprise
47
Ameriprise
Minnesota
$845K -$5.24K -1,255 -0.7%
PP
48
PDT Partners
New York
$845K +$722K +173,084 +1,086%
UBS AM
49
UBS AM
Illinois
$761K +$56.7K +13,578 +9%
ECM
50
ExodusPoint Capital Management
New York
$729K -$1.25M -299,804 -65%
1
2
3 4 5

ALLO Hedge Fund Activity: Q1 2024 in Review

161 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q1 2024, worth a combined $586M — up 47% from $398M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of ALLO and 23 opened new positions — a net loss of 9 holders — while 46 trimmed existing stakes and 54 added.

The largest buyer was State Street, adding an estimated $28.2M. The largest seller was Goldman Sachs, cutting an estimated $8.52M.

  • 161 institutional investors held Allogene Therapeutics (ALLO) as of Q1 2024, down from 170 in Q4 2023.
  • Funds reported $586M of Allogene Therapeutics stock for Q1 2024, up 47% quarter-over-quarter.
  • 23 funds opened new Allogene Therapeutics positions in Q1 2024 and 32 closed out, a net change of -9 holders.
  • The largest Allogene Therapeutics buyer in Q1 2024 was State Street, an estimated $28.2M added.
  • The largest Allogene Therapeutics seller in Q1 2024 was Goldman Sachs, an estimated $8.52M sold.

Based on aggregated 13F filings for Q1 2024.